Hester Biosciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,909	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.8	2.8	5.6	12.7	13.2
7.6	7.6	12.4	11.1	8.8
188	188	208	239	268
2,102	—	—	—	—
185	185	202	226	255
₹2,470.62	—	—	—	—

556	556	534	542	557
33.9%	33.9%	38.9%	44.1%	48.2%
0.09×	—	—	—	—

6.45×	—	—	—	—
24.26×	—	—	—	—
32.40×	—	—	—	—
45.38×	—	—	—	—
326	333	311	305	266
86.6	86.7	61.1	53.7	50.6
64.9	67.8	44.3	36.5	29.9
—	64.1	64.5	48.1	23.6
46.3	46.3	43.9	23.7	−54.2
—	44.6	39.9	17.8	−58.4
—	17.8	20.6	24.4	77.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,909 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,908.7
- Cash, Equiv & ST Investments	13.2	12.7	5.6	2.8	2.8
+ Minority Interest	8.8	11.1	12.4	7.6	7.6
+ Total Debt	268.2	239.0	207.8	188.3	188.3
Enterprise Value	—	—	—	—	2,101.8
Net Debt (memo)	255.0	226.3	202.2	185.5	185.5
EV per Share	—	—	—	—	2,470.62

Total Capital	556.7	541.9	534.4	556.0	556.0
Total Debt/Total Capital	48.17	44.11	38.88	33.86	33.86
Total Debt/EV	—	—	—	—	0.09

EV/Sales	—	—	—	—	6.45
EV/EBITDA	—	—	—	—	24.26
EV/EBIT	—	—	—	—	32.40
EV/Free Cash Flow	—	—	—	—	45.38
Reference Items — Trailing FY Values
Sales	266.1	304.5	311.1	332.6	325.7
EBITDA	50.6	53.7	61.1	86.7	86.6
EBIT	29.9	36.5	44.3	67.8	64.9
Operating Cash Flow	23.6	48.1	64.5	64.1	—
Free Cash Flow	-54.2	23.7	43.9	46.3	46.3
FCFF (free cash flow to the firm)	-58.4	17.8	39.9	44.6	—
Capital Expenditure	77.8	24.4	20.6	17.8	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.